A Study to Determine the Effectiveness and Safety of a New Nicotine Replacement Therapy

Overview

About this study

The purpose of this study is to assess the effectiveness and safety of a new nicotine product for continuous abstinence from smoking. Effectiveness of the product will be evaluated by assessments of patient reported abstinence, and verified by exhaled carbon monoxide (CO) levels.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Males or females
  • 18-85 years of age
  • Currently smoke cigarettes daily and are willing to stop smoking

 

Exclusion Criteria

  • History of cardiovascular disease, stomach ulcer or diabetes unless physician's written approval is obtained
  • Use of other forms of tobacco/nicotine containing products other than cigarettes within 30 days before baseline visit
  • Use of nicotine replacement therapies or other smoking cessation medicines/non-drug therapies within 30 days before the baseline visit
  • Pregnancy or intending to become pregnant
  • Hypersensitivity to the product
  • History of alcohol or substance abuse

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Scott Leischow, Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available